Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of R-CEEP (Rituximab, Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) in Elderly or Unfit Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Single-Centre Experience

James Yeung, MBBS, Ashlea Campbell, BSc MBBS FRACP FRCPA, Christian E Bryant, MBBS PhDFRACP FRCPA, Liane Khoo, MBBS PhDFRACP FRCPA, Scott Dunkley, MBBS FRACP FRCPA, Harry J Iland, MBBS FRACP FRCPA MHGSA, Stephen R Larsen, MBBS PhDFRACP FRCPA, Susan Moreton, MBBS FRACP FRCPA, Douglas E Joshua, BSc(Hons) MBBS DPhil FRACP FRCPA, Vinay Vanguru, MBBS FRACP FRCPA, Derek A McCulloch, BSc MBBChir PhDFRACP FRCPA, Danny Hsu, MBBS FRACP FRCPA, John Gibson, MBBS PhDFRACP FRCPA, P. Joy Ho, MBBS DPhil FRACP FRCPA, Christina Brown, MBBS PhDFRACP FRCPA

Blood (2019) 134 (Supplement_1): 2911.

https://doi.org/10.1182/blood-2019-131589

Published: 2019

Journal Articles

First Report on the Safety and Efficacy of a Long-Acting Recombinant FVIII (turoctocog alfa pegol, N8-GP) during Major Surgery in Patients with Severe Hemophilia a

Kingsley Hampton, Pratima Chowdary, Scott Dunkley, Silke Ehrenforth, MD PhD, Lotte Jacobsen, Anne T. Neff, MD, Elena Santagostino, MD PhD, Jameela Sathar, Hideyuki Takedani, Clifford M. Takemoto, MD, Claude Négrier

Blood (2015) 126 (23): 2283.

https://doi.org/10.1182/blood.V126.23.2283.2283

Published: 2015

Journal Articles

Coagulopathy Is a Strong Independent Predictor Of In-Hospital Mortality Following Massive Transfusion: Initial Results From The Australian and New Zealand Massive Transfusion Registry (ANZ-MTR)

Amanda J Zatta, BSc (Hons), PhD, Zoe K McQuilten, MBBS, Nick Andrianopoulos, MBBS, MBiostat, David J Roxby, MBBS, Naomi J Aoki, BSc, MSc, Krishna Badami, MBBS, Larry McNicol, MBBS, Ken Davis, BSc (Hons), Scott Dunkley, MBBS, Catherine Hurn, MBBS, Louise E Phillips, BSc(Hons), MPH, PhD, James P Isbister, MBBS, Peter A Cameron, MBBS, PhD, Erica M Wood, MBBS

Blood (2013) 122 (21): 2402.

https://doi.org/10.1182/blood.V122.21.2402.2402

Published: 2013

Journal Articles

Safety and Efficacy of CEEP (Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) with or without Rituximab in Elderly Patients (>70) with Diffuse Large B-Cell Lymphoma (DLBL): A Retrospective Single Center Experience

Danny Hsu, MBBS FRACP FRCPA, Ibrahim Tohidi-Esfahani, MBBS, Christina Brown, MBBS PhD FRACP FRCPA, Scott Dunkley, MBBS FRACP FRCPA, Stephen Robert Larsen, MBBS FRACP FRCPA PhD, Phoebe Joy Ho, MBBS FRCPA FRACP DPhil, Harry Iland, MBBS FRACP FRCPA MHGSA, John Gibson, MBBS FRACP FRCPA DPhil, Douglas E. Joshua, MBBS DPhil FRACP FRCPA AM

Blood (2011) 118 (21): 4957.

https://doi.org/10.1182/blood.V118.21.4957.4957

Published: 2011

Journal Articles

Recombinant Activated Factor VII for Bleeding In the Setting of Malignancy or Hematopoietic Stem Cell Transplantation: The Australian and New Zealand Experience, 2000–2009,

Mark N Polizzotto, MBBS, BMedSc, Amanda J Zatta, BSc (Hons), PhD, Merrole F Cole-Sinclair, MBBS, BSc (Hons), Erica M Wood, MBBS, Zoe K McQuilten, MBBS, Scott Dunkley, MBBS FRACP FRCPA, Peter Cameron, MBBS, PhD, Louise E Phillips, BSc (Hons), MPH, PhD

Blood (2011) 118 (21): 3311.

https://doi.org/10.1182/blood.V118.21.3311.3311

Published: 2011

Journal Articles

Ten Years and Over 3600 Cases of Recombinant Activated Factor VII Use: What Does the Haemostasis Registry Data Tell Us?

Louise E Phillips, BSc, (hons), MPH, PhD, Amanda J Zatta, BSc, (Hons), PhD, James Isbister, MD, Scott Dunkley, MD, John McNeil, MD, PhD, Peter Cameron, MD, PhD

Blood (2010) 116 (21): 3352.

https://doi.org/10.1182/blood.V116.21.3352.3352

Published: 2010

Journal Articles

Adherence to Transfusion Protocols and the Use of Recombinant Activated Factor VII.

Louise E Phillips, BSc, (Hons), PhD, Cameron Willis, PhD, Amanda Zatta, PhD, Scott Dunkley, BMed(hons), FRACP, FRCPA, Peter Cameron, MD, MBBS, FACEM, Hatem H. Salem, MD, FRACP, FRCPA, James Isbister, MB, BS, BSc(MED), FRACP, FRCPA

Blood (2009) 114 (22): 4192.

https://doi.org/10.1182/blood.V114.22.4192.4192

Published: 2009

Journal Articles

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Blood (2009) 114 (22): 1125.

https://doi.org/10.1182/blood.V114.22.1125.1125

Published: 2009

Journal Articles

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Blood (2008) 112 (10): 3965–3973.

https://doi.org/10.1182/blood-2008-06-161737

Published: 2008

Includes: Supplemental data

Journal Articles

The Use of Recombinant Activated Factor VII in Australia and New Zealand.

Scott Dunkley, Peter A. Cameron, MBBS FACEM MD, Louise E. Phillips, BSc (Hons) PhD, James Isbister

Blood (2006) 108 (11): 4025.

https://doi.org/10.1182/blood.V108.11.4025.4025

Published: 2006

Journal Articles

Thrombophilia as a common predisposing factor in pseudotumor cerebri

Scott Dunkley, Ian Johnston

Blood (2004) 103 (5): 1972–1973.

https://doi.org/10.1182/blood-2003-09-3017

Published: 2004

NARROW

Safety and Efficacy of R-CEEP (Rituximab, Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) in Elderly or Unfit Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Single-Centre Experience

First Report on the Safety and Efficacy of a Long-Acting Recombinant FVIII (turoctocog alfa pegol, N8-GP) during Major Surgery in Patients with Severe Hemophilia a

Coagulopathy Is a Strong Independent Predictor Of In-Hospital Mortality Following Massive Transfusion: Initial Results From The Australian and New Zealand Massive Transfusion Registry (ANZ-MTR)

Safety and Efficacy of CEEP (Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) with or without Rituximab in Elderly Patients (>70) with Diffuse Large B-Cell Lymphoma (DLBL): A Retrospective Single Center Experience

Recombinant Activated Factor VII for Bleeding In the Setting of Malignancy or Hematopoietic Stem Cell Transplantation: The Australian and New Zealand Experience, 2000–2009,

Ten Years and Over 3600 Cases of Recombinant Activated Factor VII Use: What Does the Haemostasis Registry Data Tell Us?

Adherence to Transfusion Protocols and the Use of Recombinant Activated Factor VII.

Maintaining Imatinib ≥600 Mg Daily in the First 12 Months of Chronic Phase CML Treatment Is Associated with Superior Event-Free Survival at 5 Years.

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

The Use of Recombinant Activated Factor VII in Australia and New Zealand.

Thrombophilia as a common predisposing factor in pseudotumor cerebri

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only